

QA.15.0.0.3

**FORM 39**

[RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC

**TEST REPORT**

<b>ISSUED TO :</b> Meghalayan Medical Drugs And Services Limited New colony shillong, DHS, Iaitumkhrah, Office of the mission director, NHM, Shillong, East Khasi Hills Meghalaya, 793003 Shillong - 793003 MFG. LICENCE No :	<b>REPORT NO :</b> [REDACTED] <b>ISSUE DATE :</b> 22/11/2023 <b>CUSTOMER REFERENCE :</b> TRF <b>DATE :</b> 17/11/2023 <b>PAGE NO :</b> 1 of 3
--	---

**SAMPLE DETAILS**

<b>SAMPLE REGISTRATION DETAILS</b>	
Sample Name : Albendazole	Sample Quantity Received : 60.00 Tablets
	Sample Registration Date : 20/11/2023
	Sample Submitted/Drawn by : Client
	Batch Size : N/A
	Date of Expiry : Dec-2025
Sample Receipt Date : 17/11/2023	
Registration No : [REDACTED]	
Name of Manufacturer : N/A	
Batch No. : MMDSL QC-0022	
Date of Mfg. : Jul-2023	
<b>SAMPLE ANALYSIS DETAILS</b>	
Analysis Starting Date : 20/11/2023	Analysis Completion Date : 21/11/2023

**TEST RESULT**

Sl No.	TEST PARAMETER	TESTING / REF. PROCEDURE	LABEL CLAIM	UOM	ACCEPTANCE LIMIT	RESULTS
1	Description	Indian Pharmacopoeia 2022	-	-	Light orange colour biconvex oval shaped uncoated tablet having red specs on whole body, one side plain and other side breakline chewable tablet.	Light orange colour biconvex oval shaped uncoated tablet having red specs on whole body, one side plain and other side breakline chewable tablet.



QA.15.0.0.3


**FORM 39****[RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC****TEST REPORT**

<b>ISSUED TO :</b> Meghalayan Medical Drugs And Services Limited New colony shillong, DHS, Iaitumkrah, Office of the mission director, NHM, Shillong, East Khasi Hills Meghalaya, 793003 Shillong - 793003 MFG. LICENCE No :	<b>REPORT NO</b> : ██████████ <b>ISSUE DATE</b> : 22/11/2023 <b>CUSTOMER REFERENCE</b> : TRF <b>DATE</b> : 17/11/2023 <b>PAGE NO</b> : 2 of 3
---	---

**TEST RESULT**

SL No.	TEST PARAMETER	TESTING / REF. PROCEDURE	LABEL CLAIM	UOM	ACCEPTANCE LIMIT	RESULTS
2	Identification A	Indian Pharmacopoeia 2022	-	---	The principal spot in the chromatogram obtained with the test solution should correspond to that in the chromatogram obtained with the reference solution.	The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.
3	Identification B	Indian Pharmacopoeia 2022	-	---	Should Comply	Complies
4	Disintegration test	Indian Pharmacopoeia 2022	-	Min./Sec.	NMT 15 Mins	Min : 04 Min 26 Sec , Max : 05 Min 30 Sec
5	Dissolution	Indian Pharmacopoeia 2022	400 mg/Tab	% of L.C.	NLT 85.0	Avg :95.98 , Min :95.67 , Max : 96.29
6	Uniformity of the weight	Indian Pharmacopoeia 2022	-	%	(±)5.0	Avg wt :705.27 mg , (-) Dev :0.61, (+) Dev : 1.45
7	Assay	Indian Pharmacopoeia 2022	400 mg/Tab	% of L.C.	370.0 - 430.0 mg/Tab i.e. 92.5 - 107.5	395.36 mg/Tab i.e. 98.84

In the opinion of the undersigned, the Sample referred to above is of Standard Quality / is not of Standard Quality as defined in the Act or the Rules made there under for the reasons given below:



QA.15.0.0.3

**FORM 39**

[RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC

**TEST REPORT**

**ISSUED TO :**  
Meghalayan Medical Drugs And Services Limited  
New colony shillong, DHS, Iaitumkhrah, Office of the mission  
director, NHM, Shillong, East Khasi Hills Meghalaya, 793003  
Shillong - 793003  
**MFG. LICENCE No :**

**REPORT NO** : [REDACTED]  
**ISSUE DATE** : 22/11/2023  
**CUSTOMER REFERENCE** : TRF  
**DATE** : 17/11/2023  
**PAGE NO** : 3 of 3

**Date** : 22/11/2023

**UOM** : Unit of Measurement

**REMARKS** : The sample is tested as per test procedure shared by client and Opinion on Quality is drawn against the result obtained for tested parameter only.

**Note** :

**-END OF THE TEST REPORT-**